Evidence map›Paper›PMID 27877247›Full record

ReviewTheranostics2016

Beyond the Barriers of Light Penetration: Strategies, Perspectives and Possibilities for Photodynamic Therapy.

Srivalleesha Mallidi, Sriram Anbil, Anne-Laure Bulin, Girgis Obaid, Megumi Ichikawa, Tayyaba Hasan

Abstract readReview
In one paragraph

Review in Theranostics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 174 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
174citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

174 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Shedding light on the cancer cell death mechanism in photodynamic therapy.Apoptosis : an international journal on programmed cell death · 2026
    Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review

114 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Srivalleesha MallidiWellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA 02114.
Sriram AnbilWellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA 02114;; Howard Hughes Medical Institute, Chevy Chase, MD, 20815;; The University of Texas School of Medicine at San Antonio, San Antonio, TX 78229.
Anne-Laure BulinWellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA 02114.
Girgis ObaidWellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA 02114.
Megumi IchikawaWellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA 02114.
Tayyaba HasanWellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA 02114.

Funding

Targeted Photoactivable Nanocells: Image-based Drug Delivery and Dosimetry in GBMR01CA156177 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI HASAN, TAYYABA, POGUE, BRIAN WILLIAM · 2011 to 2015
$2.5M
Heterocellular 3D ovarian tumor arrays for imaging and mechanistic combinationsR01CA158415 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI HASAN, TAYYABA · 2012 to 2016
$2.0M
Ovarian Cancer PDT: Multi-intracellular targeting and Image-guided dosimetryR01CA160998 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI HASAN, TAYYABA · 2011 to 2015
$2.0M
Glioblastoma PDT Design: Nanoagent Uptake and Tumor Oxygenation based dosimetryF32CA165881 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI MALLIDI, SRIVALLEESHA · 2012 to 2014
$163k
Howard Hughes Medical InstituteNCI NIH HHS F32 CA165881NCI NIH HHS R01 CA156177NCI NIH HHS R01 CA158415NCI NIH HHS R01 CA160998
6 · The paper itself

Abstract

Photodynamic therapy (PDT) is a photochemistry based treatment modality that involves the generation of cytotoxic species through the interactions of a photosensitizer molecule with light irradiation of an appropriate wavelength. PDT is an approved therapeutic modality for several cancers globally and in several cases has proved to be effective where traditional treatments have failed. The key parameters that determine PDT efficacy are 1. the photosensitizer (nature of the molecules, selectivity, and macroscopic and microscopic localization etc.), 2. light application (wavelength, fluence, fluence rate, irradiation regimes etc.) and 3. the microenvironment (vascularity, hypoxic regions, stromal tissue density, molecular heterogeneity etc.). Over the years, several groups aimed to monitor and manipulate the components of these critical parameters to improve the effectiveness of PDT treatments. However, PDT is still misconstrued to be a surface treatment primarily due to the limited depths of light penetration. In this review, we present the recent advances, strategies and perspectives in PDT approaches, particularly in cancer treatment, that focus on increasing the 'damage zone' beyond the reach of light in the body. This is enabled by a spectrum of approaches that range from innovative photosensitizer excitation strategies, increased specificity of phototoxicity, and biomodulatory approaches that amplify the biotherapeutic effects induced by photodynamic action. Along with the increasing depth of understanding of the underlying physical, chemical and physiological mechanisms, it is anticipated that with the convergence of these strategies, the clinical utility of PDT will be expanded to a powerful modality in the armamentarium for the management of cancer.

Indexed as

LightHumansNeoplasmsPhotochemotherapyPhotosensitizing AgentsPhotosensitizing Agentslight penetrationphotodynamic therapy

Identifiers

PMID27877247
PMCPMC5118607

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.